Abstract Endothelial nitric oxide synthase (eNOS, NOS3) is responsible for producing nitric oxide (NO)-a key molecule that can directly (or indirectly) act as a vasodilator and anti-inflammatory mediator. In this review, we examine the structural effects of regulation of the eNOS enzyme, including post-translational modifications and subcellular localization. After production, NO diffuses to surrounding cells with a variety of effects. We focus on the physiological role of NO and NO-derived molecules, including microvascular effects on vessel tone and immune response. Regulation of eNOS and NO action is complicated; we address endogenous and exogenous mechanisms of NO regulation with a discussion of pharmacological agents used in clinical and laboratory settings and a proposed role for eNOS in circulating red blood cells.
Introduction
Nitric oxide (NO) is produced by a family of enzymes called nitric oxide synthases (NOS). There are three NOS isoforms, neuronal NOS (nNOS; NOS1), inducible NOS (iNOS; NOS2), and endothelial NOS (eNOS; NOS3), all of which differ slightly in physiological role and expression profile. nNOS is expressed in neurons and skeletal muscle and produces NO as a cellular signaling molecule. iNOS is expressed in immune cells and produces NO as a precursor to cytotoxic free radicals for defense against invading bacteria. This review focuses on eNOS, which is expressed in endothelial cells, and its role in vascular function. NO and its metabolites are found in both the macrovascular (aorta and medium arteries) and microvascular (arterioles/resistance arteries and capillaries) circulation. Endothelialderived NO acts as a potent vasodilator through diffusion to smooth muscle cells that surround vessels and decreases leukocyte adhesion to the endothelial cells, thereby affecting immune response and inflammation. To fully understand the role of eNOS and NO in the roles of whole-body blood pressure regulation and inflammatory response, the molecular structure and regulatory modifications of eNOS that affect NO production need to be understood.
eNOS structure, co-factors, and phosphorylation
Structure and cofactors
The functional form of eNOS is a homodimer [1] with each monomer containing an N-terminal oxygenase and C-terminal reductase domain connected by a central calmodulin (CaM) binding sequence ( Fig. 1) [2, 3] . Several crystal structures exist of the different domains from different X. Shu and T. C. Stevenson Keller IV contributed equally to this work.
& Brant E. Isakson brant@virginia.edu isoforms and organisms; however, the full-length structure of any of the three NOS proteins has yet to be determined. The eNOS dimer is stabilized by 5,6,7,8-tetrahydrobiopterin (H 4 biopterin) [4] and zinc [5, 6] binding to the oxygenase domain. In the human eNOS sequence, zinc binding is coordinated by cysteines 94 and 99 from each monomer and is structurally, but not enzymatically, important. H 4 biopterin binds between the interface of heme and the dimer, stabilized by Van der Waals and hydrophobic interactions [7] . In addition to stabilizing the eNOS dimer, H 4 biopterin is proposed to modulate the redox potential of the heme prosthetic group. To start the electron transfer reaction, reduced nicotinamide adenine dinucleotide phosphate (NADPH) binds to the C-terminal reductase domain of one monomer of the eNOS dimer. Within this reductase domain, an electron flows from NADPH to other bound cofactors: flavin adenine dinucleotide (FAD), followed by flavin mononucleotide (FMN). The electron then flows to the heme on the oxygenase domain of the other eNOS monomer. The dimerized , Calmodulin (CaM) binding (491-510), and reductase (756-1002) domains. All three domains contain phosphorylation sites (indicated by circles) that modulate eNOS activity (red for decreased activity and green for increased activity). b Structural model of the full length eNOS. The crystal structure of the human oxygenase domain and a homology model of the reductase domain (using the rat nNOS reductase structure (PDBid: 1TLL) as the template) are shown in a surface representation with one subunit colored gray and the other tan. The autoinhibitory loop (residues 596-640) is rendered as a cartoon for one subunit. Cofactors are rendered as spheres and colored: NADPH, green; FAD, orange; FMN, yellow; heme, red; H 4 biopterin, pink; and zinc, purple. The N-(blue) and C-terminal (cyan) are also rendered as spheres. The linker between the oxygenase and reductase domains is shown for one subunit with the letters indicating the primary sequence. Purple text highlights the CaM binding domain with the star indicating the T495 phosphorylation site. The structure of CaM bound to a peptide corresponding to the eNOS sequence is shown in purple, and the calcium-bound and unbound CaM structures are shown in shades of gray. This model is based on that proposed by Garcin et al. [11] form is essential for this activity because the electron is transferred between subunits. The reduced heme then catalyzes the synthesis of NO from the substrates of L-arginine and oxygen, creating L-citrulline as a byproduct [8] . A conformational change of the FMN binding domain is postulated such that the FMN domain ''swings'' from the reductase to the oxygenase domain in order to shuttle the electron between subunits.
The eNOS dimer is inactive without further modification due to two autoinhibitory regions (residues 596-640 (AH1) and 1165-1178 (AH2) [9, 10] ) in the reductase domain that modulate the coupling between the oxygenase and reductase domains. AH1 is postulated to interact with the flexible linker between domains (residues 481-520) and occludes the CaM binding sequence from interacting with CaM. Only the Ca 2? -bound conformation of CaM binds to eNOS, thereby connecting activation of eNOS to intracellular calcium concentration ([Ca 2? ] i ). AH2 regulates the interaction of the FMN and NADPH binding regions in the reductase domain; it is postulated to ''lock'' the FMN domain into a position optimal for electron acceptance and thus must undergo a conformational change to donate an electron to heme [10, 11] .
The N-terminus of eNOS is proposed to be predominantly unstructured and contains three acylation sites at residues 2, 15, and 26. Glycine 2 is co-translationally myristoylated and is a requirement for membrane localization. Cysteine residues 15 and 26 are post-translationally palmitoylated. The specific role of the palmitoylation is not clear, but stabilization of membrane association and/or sequestration into lipid domains has been proposed [12] . DHHC21, a palmitoyl transferase that has an Asp-His-HisCys motif, palmitoylates eNOS; its depletion affects physiological localization of eNOS, causing a subsequent decrease in NO production [13] .
Based on these structural features, there are two ways to regulate eNOS function: modulate the dimer or modulate the coupling of electron transfer from the reductase domain to the oxygenase domain while in the dimeric conformation. Both of these modes of regulation appear to occur variously through cofactor availability (e.g., a decrease in H 4 biopterin due to enhanced oxidation), post-translational modifications, cellular localization, and/or protein-protein interactions.
Regulation of eNOS by protein-protein interactions
In addition to CaM, several other proteins directly bind eNOS and modulate its activity (Table 1) . In contrast to the activating role of CaM, one of the most well characterized inhibitors of eNOS activity is caveolin-1 (Cav1). Cav1 is the main coat protein of caveolae, which are membrane microvesicles that harbor membrane-associated proteins in endothelial cells (ECs) [14] . Within caveolae, Cav1 directly associates with eNOS near the CaM-binding sequence and sterically prevents activation by CaM [15] , decreasing NO production. Other proteins interact with eNOS; these include heat shock protein 90 (HSP90) [16] [17] [18] , NOS interacting protein (NOSIP) [19, 20] , b-actin [21, 22] , and the alpha subunit of hemoglobin (alpha globin). All of these binding partners cause eNOS translocation from the plasma membrane and activate NO production, except alpha globin. HSP90 binds to eNOS residues 310-323, which are proximal to the Cav1 binding site [16] . Released from Cav1, HSP90 enhances CaM association and phosphorylation on activating residue S1177 via protein kinase B (Akt) [23], (Table 2 ) thereby increasing NO production. NOSIP binds to the C-terminal region of the oxygenase domain (residues 366-486) [24] and ubiquitinylates eNOS [20] , decreasing NO production and marking the enzyme for degradation.
b-Actin-eNOS association is directly related to oxygen capacity in the microenvironment of the EC. In hyperoxemic conditions, eNOS associates with the actin cytoskeleton via direct binding with b-actin. Although NO is an effective regulator of blood pressure and vascular function, increased NO bioavailability in an O 2 rich environment often leads to detrimental reactive oxygen species (ROS) formation.
The most recently characterized inhibitory protein partner of eNOS in the microcirculation is alpha globin [25, 26] . As discussed below, NO bioavailability is decreased by alpha globin expressed in a polarized region of the microvascular endothelial cell known as the myoendothelial junction (MEJ). This localized expression of alpha globin affects the eNOS signaling domain by directly interacting with the oxygenase domain of eNOS to inhibit NO production as well as scavenging NO via the alpha globin heme group.
Activating phosphorylation
eNOS activity can be enhanced upon phosphorylation at several residues through multiple pathways and kinases ( Table 2 ). The following is a description limited to the sites in which the activation or inhibition has been identified and the structural consequences postulated for each. Additional phosphorylation sites were recently identified (e.g. T33, S53, and S836 through proteomics approaches) [27]; however, their physiological significance has not been investigated.
Three characterized phosphorylation sites that enhance NO production are located in the autoinhibitory regions of the reductase domain (Table 2 ; S615, S633, and S1177). The introduction of negative charge at each of these sites likely disrupts the interactions of the autoinhibitory regions Table 2 ). Mutation of any one of these sites to aspartate as a phosphomimic increased NO production in cells expressing the mutant proteins [20, 28] . In addition to these sites, Y81 is phosphorylated by Src kinase and increases NO production [37, 38] ; however, the structural mechanism of activation is unknown.
Inhibitory phosphorylation
There are three well-characterized phosphorylation sites that inhibit eNOS activity (Table 2 ; S114, T495, and Y657) with different molecular consequences due to their divergent locations in the eNOS structure. S114, located in the oxygenase domain, is phosphorylated by protein kinase C (PKC) [39] and AMPK [36] . Although contradictory data exist [40, 41] , phosphorylation at S114 is more likely to reduce eNOS activity [39, 42] . S114 is located in an unresolved loop in the oxygenase domain crystal structure, away from the heme. Thus, phosphorylation at this site could inhibit activity by preventing interactions between the reductase and oxygenase domain rather than by modulating the redox activity of heme. Alternatively, S114 phosphorylation may modulate protein-protein interactions, as S114 phosphorylation is required for peptidylprolyl isomerase binding [43] and may promote eNOS interaction with Cav1.
T495 (Fig. 1b , yellow star) is located in the CaM binding sequence (Fig. 1b , purple text) and is phosphorylated by PKC (in vivo) and AMPK (in vitro) [44, 45] ( Table 2) . PKC phosphorylation at this site decreases eNOS activity by reducing the affinity of CaM [46] . The structure of CaM bound to the eNOS recognition sequence suggests that the introduction of a negative charge at position 495 destabilizes the CaM-eNOS interaction through repulsion from CaM glutamate residues 7 and 127, although other mechanisms are possible (e.g. destabilizing the helical structure of the CaM binding sequence) [47] .
Y657 is phosphorylated by the proline-rich tyrosine kinase 2 (PYK2) ( Table 2 ) and decreases eNOS activity [48] . Without phosphorylation, this particular residue directly interacts with FMN through pi-pi stacking [11] . Its phosphorylation may modulate the reduction potential of FMN or the dynamics of the FMN binding domain, thereby decreasing the efficiency of electron transfer within the eNOS dimer.
Summary of eNOS regulation
Describing each regulatory element independently provides an unrealistic perspective of eNOS regulation. Phosphorylation or dephosphorylation at each of the aforementioned sites, protein-protein interactions, and the bioavailability of cofactors can occur simultaneously, and all or combinations of these events may regulate eNOS activity. For instance, AMPK phosphorylates both an activating (S1177) and inhibiting (S114) eNOS site. In addition, many stimuli influence multiple pathways that regulate eNOS activity. The well-characterized vasodilator bradykinin stimulates NO synthesis by promoting S1177 phosphorylation [33] and T495 dephosphorylation [49] . Fluid shear stress signals through a cascade resulting in phosphorylation of eNOS S114 (decreasing NO production), S633 (increasing NO production), Y657 (decreasing NO production), and S1177 (increasing NO production) [48, 50] . This complexity requires a careful and thorough understanding of the cellular system and stimuli, as well as a cumulative understanding of the regulatory processes at work.
Localization of eNOS within the microvascular endothelium
Within microvascular EC, the vast majority of eNOS is localized to plasma membrane caveolae and associated with Cav1. The lipid composition of caveolar membrane domains is crucial for normal eNOS localization and activation. Normally, cholesterol is enriched in caveolae, and disruption or depletion of cholesterol concentrations causes redistribution of eNOS to an intracellular compartment and decreased NO production [58] . The signaling phosphosphingolipid ceramide is also able to activate eNOS independently of calcium in cultured macrovascular endothelial cells [59] , though this mechanism may be different in the microvasculature or in vivo.
In addition to localizing to caveolae and the Golgi membrane, eNOS can be localized to mitochondria, perinuclear regions, and the actin cytoskeleton, but these pools of enzyme contribute less to total NO production compared to the eNOS present in the Golgi membrane and plasmalemmal caveolae. Active eNOS associates with the cytoplasmic cis face of the Golgi apparatus, as evidenced by colocalization with mannosidase [60, 61] and association with DHHC21. In the cardiac microvasculature, eNOS expression is higher in total arterial versus venous endothelium, and this difference may be due to a greater level of Golgi association in the coronary arteries [62] . eNOS expression has been shown to be higher in venules than arterioles, but there is still some controversy over the differences between arterial and venous expression and activity of eNOS. Wagner et al. hypothesized that the high eNOS activity in arterial ECs reflects a role in regulating arteriolar tone and that venular-derived NO plays a key role in local thrombosis [63] . The differential regulation and function of eNOS in arterioles and veins is further shown by experiments where, during thrombosis, inhibition of eNOS had no effect on arterioles but induced an increase of leukocyte adhesion in venules [64] . These results could support the idea that there are differences in eNOS function between arterioles and venules, showing the role of eNOS in regulating arteriolar vasodilation and venous inflammation.
Using NO or ROS for vasodilation
The ultimate goal in understanding production of NO or reactive nitrogen species is to contextualize the resulting physiological effects. To regulate blood pressure, NO Endothelial nitric oxide synthase in the microcirculation 4565 produced in ECs relaxes adjacent SMCs, causing dilation and lowering total peripheral resistance. In the resistance arterial vasculature, eNOS is responsible for 20-50 % of dilation [52, [65] [66] [67] [68] [69] [70] [71] [72] , with endothelium derived hyperpolarization (EDH) accounting for the rest. However, NO appears to be responsible for a higher percentage of dilation in the conduit arteries (up to 100 % of the dilatory component) [73] [74] [75] [76] . The contribution of NO bioavailability to dilation declines as the vascular tree progresses from being predominantly a pressure reservoir in large conduit arteries to a highly regulated distribution network in the capillaries, but cannot be simply explained by expression levels, as eNOS is located throughout different vascular beds [77] . Several mechanisms could account for the reduction in reliance on NO bioavailability for dilation in the microcirculation.
Post-translational modifications
Differential post-translational modifications of eNOS could alter eNOS function and activity in each level of the vascular tree [78] [79] [80] . As discussed above, eNOS phosphorylation is a key regulator of eNOS activity. The hemodynamic profile within blood vessels (specifically shear stress) impacts the activity of eNOS. While reports of shear stress throughout the vascular system are variable and depend on the vascular bed, methods of measurement, and animal model, there is agreement that conduit and large arteries are sensitive to shear stress, while areas with low shear stress experience lower NO bioavailability and increased plaque development [81] [82] [83] [84] [85] . Indeed, eNOS is upregulated and activated (via phosphorylation of S1177) in rabbit carotid arteries in areas of high shear stress [86] . Further evidence, also using in vivo measurements in rabbits, showed significantly lower expression of eNOS in coronary arteries compared to the aorta, which correlates well with hemodynamic signaling [87] . In porcine vasculature, large conduit arteries that experience increases in wall shear stress positively correlate with eNOS expression [88] . In porcine coronary arteries and arterioles, eNOS expression decreases as the vessels decrease in size [89] , although shear stress was not measured in the latter study. This observation highlights apparent distinctions between large and resistance vessels, which include eNOS expression and activation via sensitivity to shear stress. There are currently no well-defined differences in eNOS post-translational modifications from arteries to arterioles that definitively explain the decreased reliance of arterioles on NO for dilation. While some uncertainty exists, vascular beds do regulate eNOS activity through differences in posttranslational modifications; these remain intriguing therapeutic targets in hypertensive pathologies.
Localization
Subcellular localization of eNOS (see above) [79, 80, 90] could account for the variation in eNOS activity observed. Activation of the caveolar and Golgi pools of eNOS via S1177 phosphorylation occurs by two different mechanisms, with caveolae-associated eNOS being more sensitive to [Ca 2? ] i fluxes and Golgi-associated eNOS being more sensitive to Akt phosphorylation [61] . Subcellular localization of eNOS affects functionality, and Golgi-localized eNOS is indicated to play an important role in the S-nitrosylation of proteins [91] . Given its close proximity to calcium currents and the larger amount of NO it produces, plasma membrane-bound eNOS in caveolae has a greater effect on SMC relaxation through cGMP signaling [61, 92] . Thus eNOS in microvascular ECs may be preferentially located in the Golgi (for S-nitrothiols) or caveolae (for direct NO production) depending on the vessel diameter.
Scavenging
NO may be present throughout the vasculature but is scavenged, allowing for EDH to dominate the dilatory component of resistance arteries. This observation is supported by recent research identifying alpha globin in EC [93] and noting its enrichment at MEJs. Alpha globin is a potent scavenger of NO, and in ECs, the oxidation state of its heme dictates either NO diffusion into the SMCs or irreversible NO scavenging [26, 94] . eNOS was also found to be enriched at the MEJ and forms a macromolecular complex with alpha globin [25, 94, 95] . When the eNOS/ alpha globin complex was disrupted, the functional outcome was increased NO bioavailability and lower blood pressure in mice [25] . Given the spatial limitations found at the MEJ, and knowing that MEJs increase in frequency from proximal to distal arteries, it is postulated that alpha globin serves as a ''sink'' for NO, irreversibly scavenging NO production from eNOS [96] . Together, the subcellular localization of eNOS to the MEJ could provide an explanation for the diminished impact of NO in the vasodilation of resistance vasculature, largely due to the increased frequency of MEJs (and alpha globin) that serve as gateways to inhibit NO bioavailability to SMC and allow for EDH to predominate in driving vasodilation.
ROS and vessel size
Differences in the levels of reactive oxygen species (ROS) and by-products generated by NO between small resistance and large conduit arteries may be responsible for the differences in NO dilatory abilities. ROS could serve as second messengers or activators of selective channels within vascular beds [97, 98] . Vascular cells have been shown to have different oxidant profiles across the vascular tree [99] . For example, the cerebral circulation is abundantly supplied with NOX and superoxide, more so than other vascular beds, and these compounds have strong dilating effects on the basilar and middle cerebral arteries [99] . These effects were limited in the aorta, carotid, and mesenteric arteries; but dilation in response to acetylcholine was similar across all vessels in the same study.
Although Src , resulting in eNOS phosphorylation at Y418 (via autophosphorylation) and Y215 (an SH2-domain), both of which are inhibited by antioxidants [105] . H 2 O 2 -induced pp60
Src activation stimulates eNOS activity via downstream PI3 kinase and KT1 and appears to be both concentration-and time-dependent in its resulting effects; i.e., H 2 O 2 stimulates activity at lower levels [104] but inhibits eNOS activity at higher levels [104] .
Role of eNOS in microcirculatory inflammation
In addition to causing vasodilation, NO also has an important anti-inflammatory effect on the microvasculature. NO has been shown to inhibit neutrophil aggregation in vitro [106] and leukocyte adhesion in mesenteric arterioles [107] . Inhibition of eNOS activity has more recently been shown to cause inflammation: chronic inhibition of NO synthesis by L-NAME results in increased expression of leukocyte adhesion molecules, proliferating cell nuclear antigen (an indicator of cellular invasion and proliferation), and chemokines such as monocyte chemotactic protein-1 (MCP-1) [108, 109] . NO inhibition, in turn, leads to characteristics of acute inflammation such as increased microvascular permeability and protein leakage, as well as increased rates of leukocyte adhesion and emigration in venules [110, 111] . Furthermore, overexpression of eNOS has been shown to inhibit leukocyte adhesion molecule expression and monocyte infiltration in the context of hypercholesterolemia [112] .
The central anti-inflammatory role of eNOS-derived NO has also been shown in numerous inflammatory diseases. The expression and activity of eNOS compared to iNOS is a factor in the development and outcome of inflammation [113, 114] . During gastric ulcers, inflammatory processes are related to an imbalance between NO derived from eNOS and iNOS: eNOS expression was reduced during inflammation, and iNOS expression increased [115] [116] [117] [118] . The balance between eNOS/iNOS activity in gastric microcirculation was studied using LYSO-7, a peptide with the ability to activate peroxisome proliferator-activated receptors (PPAR) and to inhibit cyclooxygenase (COX). LYSO-7 restored gastric microcirculatory blood flow and impaired neutrophil influx; however, L-NAME partially inhibited the protective effect of LYSO-7 and led to increased gastric lesions [113, 119] .
A key initiation event in acute inflammation is leukocyte adhesion to vascular ECs. The expression of adhesion molecules on the surface of activated leukocytes and/or ECs influences the adhesive interaction of leukocytes and ECs in postcapillary venules [120] . eNOS and eNOSderived NO can inhibit this event by regulating the presentation of adhesion molecules, altering their expression in immune cells, or interfering with leukocyte-endothelial cell interaction. eNOS activity inhibits endothelial adhesion molecule expression in the murine lung and attenuates post-ischemic inflammatory injury by suppressing vascular cell adhesion molecule (VCAM) mRNA and protein expression [121] . Furthermore, NO inhibits both the expression of MCP-1 and monocyte adhesion induced by cytokines and oxidized low density lipoproteins (LDL), which also reduces VCAM-1 expression [109, [122] [123] [124] . In addition, eNOS activity either inhibits expression of the leukocyte adhesion molecule CD11/CD18 [107] or suppresses the ability of this molecule to bind to the endothelial cell surface [110] . In a severe combined immunodeficiency (SCID)-human mouse model and in human umbilical venous endothelial cells (HUVECs), the inhibition of endogenous NO production results in enhanced rolling and adhesion of human leukocytes. This induced increase in rolling is P-and E-selectin-dependent [124] . Likewise, eNOS knockout mice showed an increased expression of P-selectin [125] . Leukocyte rolling and adhesion in mesenteric venules were blocked by P-selectin-specific antibodies and a high-affinity P-selectin Endothelial nitric oxide synthase in the microcirculation 4567 ligand [125] [126] [127] . These observations show possible antiinflammatory mechanisms of eNOS-derived NO via inhibition of inflammatory processes. The activation of EC during inflammation interferes with basal EC function and could lead to endothelial dysfunction if inappropriately activated or left unresolved. Endothelial dysfunction includes the loss of NO production, which has been shown after tumor necrosis factor alpha (TNFa) treatment and subsequent decrease of eNOS expression [128] [129] [130] as well as during inflammation via oxidative stress and eNOS uncoupling [115] . Multiple studies show reduced NO bioavailability as a result of oxidative stress. The latter occurs through an imbalance between the production and breakdown of ROS [130] and is speculated to be a major cause underlying endothelial dysfunction. The reduced levels of NO released under inflammatory conditions in response to acetylcholine could thus be a result of ROS interacting with either NO or eNOS. As reported above, NO can react directly with O 2 -to form ONOO - [131] . Diminished eNOS activity or expression through ROS influence has also been demonstrated in an animal model of inflammation [114] . Additionally, ONOO -could lead to eNOS uncoupling by oxidizing the eNOS cofactor H 4 biopterin and causing eNOS to synthesize O 2 -instead of NO [132] . Scavenging of ROS could increase NO bioavailability and present a possible regulation point during inflammatory conditions [114] .
Role of eNOS in the microcirculation during sepsis-integrating reactivity and inflammation
Sepsis is systemic inflammation in response to an infection and is manifested by two or more systemic inflammatory response syndrome criteria [133] . Severe sepsis associated with organ dysfunction is correlated with high morbidity and mortality rates. The pathophysiology of sepsis includes activation of immune cells and inflammatory mediators as well as release of pro-inflammatory cytokines and vasoactive substances such as NO [134] . NO contributes to a sepsis-induced drop in blood pressure by greatly dilating the resistance arteries and decreasing peripheral resistance. A central process during sepsis is the induction of microvascular inflammation, including alteration of EC function [133] that is associated with the increase of both eNOS and iNOS within the first few hours of sepsis [135] [136] [137] , subsequent activation of iNOS, and a decrease of eNOS activity [138] . After 6-48 h of lipopolysaccharide (LPS)-induced sepsis in rats, the expression and activity of eNOS was decreased. Furthermore, eNOS activity was downregulated by diminished phosphorylation in vitro and within a complex animal model [139, 140] . In WT and eNOS KO mice with cecal ligation and puncture (CLP)-induced sepsis, increased leukocyte and platelet adhesion was detected. In this study, eNOS KO mice or mice treated with L-NAME had an increase in blood cell recruitment in the hepatic microvasculature following CLP [141] . Treatment with pravastatin, a member of the statin class of drugs used to lower high cholesterol and triglycerides, resulted in increased eNOS function and expression in LPS-injected rats, leading to improvement of eNOS-mediated vessel relaxation [23] . Additionally, overexpression of eNOS led to improved resistance to LPS-induced hypotension and death [142] . Platelet-endothelial cell interactions in mice after LPS injection could be inhibited by application of a NO donor and could be increased by NOS inhibitors or eNOS deficiency [143] . eNOS-derived NO thus seems to have a protective effect by preventing accumulation of platelets and leukocytes, with beneficial results on sepsis development and outcome [144] .
Possible pharmacological intervention for NO in the microcirculation
In clinical settings, the effects of NO have been known for over a century [145] . Before the therapeutic mechanism was known, successful treatment of vascular diseases was achieved by oral doses of nitroglycerin. NO is released from organic molecules by enzymatic processing; e.g., nitroglycerin is converted to NO via xanthine oxidoreductase and mitochondrial aldehyde dehydrogenase [146] . Other organic molecules can deliver NO in physiologic conditions, but applications are more limited because of cytotoxic effects [147] . A classic example, sodium nitroprusside, interacts with hemoglobin to release NO and a relatively large amount of cyanide, thereby undermining its long-term therapeutic effectiveness [148] . NO is a prime target for the treatment of hypo-or hypertension. Increased NO release yields decreased blood pressure (an effective, if short term, treatment of hypertension), while reduced NO release inhibits vasodilation, effectively increasing blood pressure to combat hypotension. Thus, control of eNOS enzymatic activity is an important tool for therapeutic regulation of blood pressure.
Pharmacological intervention to activate or inhibit eNOS represents an important component in treatment of cardiovascular disease, although one that would require tight regulation. All human NOS isoforms (including eNOS, nNOS, and iNOS) require dimerization for efficient production of NO [149] [150] [151] . NOS monomers first form a ''loose dimer'' via inter-molecular cysteine coordination to the heme group. The initial homodimer interaction are subsequently stabilized by binding BH 4 and the substrate, L-arginine [152] . Some imidazole-containing molecules can bind competitively in the L-arg pocket and prevent dimerization [153, 154] . L-nitroarginine methyl ester (L-NAME) is a common reagent for in vivo inhibition of NO production because L-NAME is converted to L-nitroarginine by cellular esterases. L-nitroarginine does not undergo the oxidation reaction that converts L-arg to Lcitrulline, thus inhibiting NO production by limiting substrate/enzyme interaction. These effects are dosedependent and can be overcome by a sufficient saturation with L-arg [150] . Although commonly used as an in vitro inhibitor of eNOS, L-NAME has been used clinically as a therapy for hypotension as a result of septic shock [155, 156] . The target of the therapy is usually iNOS, although L-NAME is a general NOS inhibitor because it is a competitive inhibitor of the normal substrate.
Recent advances in manipulating eNOS activity have come through peptide-based regulation. Small peptides (10-20 residues) that mimic the binding sequences of interaction partners can be used to disrupt activating or inhibiting interactions. One method of molecular control of eNOS is by controlling interactions with Cav1 [157, 158] . In caveolae, eNOS is spatially localized with Cav1, facilitating direct interaction. Residues 82-101 (the scaffolding domain) of Cav1 are responsible for binding to eNOS [159] . To further study the interaction, alanine substitution in the Cav1 peptide allowed for functional output studies of critical residues. F92 is the critical residue in Cav1 that inhibits NO production by interrupting an interaction of W445 with H 4 biopterin [160] . Mutation of F92 abrogates the inhibitory activity of the Cav1 peptide. In vivo results show that simultaneous delivery of F92 and A92 Cav1 peptides does not abolish NO production completely-the tighter binding affinity of the A92 peptide (23 nM compared to 49 nM for the F92 peptide) competitively decreases the inhibitory interaction of Cav1 [160, 161] .
Another inhibitory regulator of eNOS and NO-induced vasodilation is alpha globin. In the regulation of vascular tone, alpha globin acts in two ways: as a scavenger of NO in the MEJ [26] , and as a direct inhibitor of eNOS comparable to Cav1 [93, 157, 159] . Evidence for the direct inhibition of eNOS comes from co-immunoprecipitation of alpha globin and eNOS [25] . In the same study, a synthetic alpha globin peptide mimicking putative binding residues of alpha globin abrogated the interaction between native alpha globin and eNOS in vivo, leading to a significant decrease in blood pressure.
Both peptide therapeutics mentioned have achieved success in vivo [25, 157, 160, 161] , but no human clinical data is yet available. However, laboratory data suggest promising results for peptide-based therapy targeting eNOS.
Role of eNOS in red blood cells?
Until recently, red blood cells (RBCs) have been viewed predominantly as a site of NO consumption due to the large propensity of hemoglobin to scavenge NO [162] [163] [164] [165] . In this context, the possibility of NO production in RBCs was considered unlikely [166] . However, the story may be more complex than previously assumed. NO consumption rates in RBCs are two orders of magnitude lower than cell-free hemoglobin [165] , likely due in part to decreased interactions between RBC-bound hemoglobin and NO in the lumen [167, 168] . Potential barriers to NO scavenging by hemoglobin on RBCs include an RBC-free zone at the periphery of the vessel lumen (where NO is produced) [163, 164] and RBC membranes inhibiting NO diffusion into the circulating cell [162] .
The presence of NOS in RBCs has been reported by multiple groups with varying details. Circa 2000, studies stated that both eNOS and iNOS are present in RBCs [169, 170] , though Kang et al. reported that RBC NOS isoforms were not catalytically active. Furthermore, both groups hypothesized that if functional NOS were expressed on RBCs, the observed ability of RBC hemoglobin to scavenge NO from its surroundings would be compromised by competitive binding of locally-produced NO [170] . In contrast, more recent evidence has been presented to suggest that RBCs universally express a catalytically active eNOS on the inner leaflet of the plasma membrane and in the cytoplasm [166, 171] . RBC eNOS may also play an important role in both routine and diseased vascular function, as its activity and impairment was found to correlate with flow-mediated vessel dilation and endothelial dysfunction, respectively [171] . Other research suggests that RBC eNOS contributes to circulating nitrite levels, which may play a role in blood pressure regulation [172] .
Though subject to some controversy, RBCs may be an important source of NO in the microvasculature. Under normoxic conditions, more NO may be produced in RBCs than any other cellular compartment [171] , and NO production by RBC eNOS could have multiple physiological functions. One hypothesis is that RBC eNOS can create an ''NO shield'' against scavenging by RBCs, preventing interruption of intracellular signaling [171] . Furthermore, shear stress in hypoxic conditions has been indicated to activate RBC eNOS [173] , which in turn could play an important role in the regulation of RBC deformability to ensure adequate perfusion and oxygen distribution [174] . This proposed function in particular suggests the potential for importance of NO from RBC eNOS in regulation of vascular flow. Finally, a broader RBC endocrine-or ''erythrocrine''-function has recently been proposed in which RBCs provide systemic NO regulation throughout Endothelial nitric oxide synthase in the microcirculation 4569 the vasculature (see [175] for details). Thus, an emerging perspective may be that much of the NO interacting with RBCs is produced locally, and that RBCs provide a transport function involved in the localization of NO signaling.
A major remaining question is to what extent RBCs represent an in vivo sink for vascular NO, and how this role is altered among different physiological regions and pathological states (e.g., across a range of blood oxidation levels or other variations in blood chemistry). Even when considered simply as a sink for NO, the role of RBCs in this context could be more dynamic than initially assumed if RBC eNOS can locally provide a shielding effect against NO scavenging. The variable extent of an RBC eNOS shielding effect could conceivably modulate the impact of NO release from other sources, such as eNOS in the endothelium, by allowing a given RBC to scavenge less or more NO from its surroundings. The possibility of this phenomenon is relevant to the study of NO regulation of local myogenic tone and inflammation. Additionally, the ability of RBCs to influence the speciation of nitrogen oxide metabolites could define the potential of these cells as major signaling players in the vasculature. The ability of RBCs to scavenge and release NO in various settings suggests that they may be capable of activating or inhibiting NO signaling pathways in response to changes in blood chemistry across the vascular tree. Because of the key role of RBCs in the microcirculation, this potentially important site of NO generation requires further investigation in the contexts of vasodilation and inflammation.
Conclusions
The eNOS enzyme and its key derivative NO play an everexpanding and important role in microvasculature function. Novel pharmacological agents being designed towards the regulation of eNOS make it an exciting area of research, as does the possibility that the enzyme is harbored by cell types beyond the endothelium. Furthermore, ongoing study of reactive oxygen and nitrogen species could inform another layer of eNOS regulation. Further research into eNOS function and NO signaling holds the potential for important physiological understanding and pharmacological opportunities. 
